ResearchPod Summary
Researchers sought to determine if the broadly neutralizing antibody (bnAb) VRC01 could prevent HIV-1 acquisition in high-risk populations. While antiretroviral preexposure prophylaxis (PrEP) is effective, there is a clinical need for alternative, long-acting biomedical prevention strategies.
The study consisted of two parallel, randomized, double-blind, placebo-controlled trials: HVTN 704/HPTN 085 (involving cisgender men and transgender persons in the Americas and Europe) and HVTN 703/HPTN 081 (involving heterosexual women in sub-Saharan Africa). Participants received either a low dose (10 mg/kg) or high dose (30 mg/kg) of VRC01, or a placebo, via intravenous infusion every 8 weeks for a total of 10 infusions. The primary endpoint was the prevention of HIV-1 acquisition over 80 weeks. Researchers also performed detailed in vitro sensitivity testing (using the TZM-bl assay) on all HIV-1 strains acquired by participants to determine if the antibody's efficacy was linked to the specific viral strain's susceptibility.
VRC01 did not demonstrate a statistically significant reduction in overall HIV-1 acquisition compared to placebo in either trial. However, secondary analyses revealed a clear relationship between the antibody's efficacy and the in vitro sensitivity of the infecting virus. For HIV-1 isolates that were highly sensitive to VRC01 (IC80 < 1 μg/mL), the estimated prevention efficacy was 75.4%. Conversely, the antibody provided no protection against strains with intermediate or high resistance. Furthermore, breakthrough infections in the VRC01 groups involved viruses that were significantly more resistant to neutralization than those found in the placebo groups, suggesting that the antibody exerted selective pressure on the virus.
This study provides a critical proof-of-concept that bnAbs can effectively prevent HIV-1 acquisition, provided the circulating virus is susceptible to the antibody. The results highlight that the primary limitation of using a single bnAb like VRC01 is the natural diversity and resistance of circulating HIV-1 strains. This finding suggests that future prevention strategies should focus on using combinations of multiple, more potent bnAbs to achieve broader coverage and overcome viral resistance.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.